GS-626510 is primarily investigated for its potential therapeutic applications in the treatment of viral infections, particularly those caused by RNA viruses. It has shown promise as an antiviral agent, specifically in targeting viral replication processes. Research indicates its effectiveness in inhibiting viral polymerases, which are crucial for the replication of viral genetic material. This mechanism makes it a candidate for treating diseases such as hepatitis C and other related viral infections. Additionally, its role in clinical trials highlights its potential to be part of combination therapies, enhancing the efficacy of existing antiviral treatments. Ongoing studies aim to further explore its safety, pharmacokinetics, and broader applicability in combating emerging viral pathogens.